Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Anti-Infective Agents

Antirheumatic Agents

All Drugs and Chemicals

Hydroxychloroquine

Antimalarials

Antiprotozoal Agents

Antiparasitic Agents

Enzyme Inhibitors

HC orally for 14 days prior to nephrectomy

Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.

Hydroxychloroquine (HC)

Jodi K. Maranchie, MD

The main goal of this research study is to determine whether treating patients with renal cell cancer with hydroxychloroquine before surgery can make the cancer easier to kill. Another goal is to see how the study drug affects the body's immune cells which fight cancer cells.

Autophagy is a cellular survival mechanism that protects from stress-induced programmed death. Autophagy may enable renal cancer to escape from cytokine therapy, cytotoxic chemotherapy or targeted agents. Hydroxychloroquine prevents autophagy by blocking acidification of lysosomes, and is being studied in clinical trials as a means of enhancing of cancer therapy. This phase Ib clinical trial will test the hypothesis that pre-operative exposure to HC reduces biologic markers of autophagy in peripheral blood, normal kidney and renal cancer specimens obtained at the time of nephrectomy. These data will be used in the design and pharmacodynamic monitoring of future therapeutic trials of HC in combination with high dose interleukin-2 and other systemic therapies for advanced RCC.

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

A Phase IB Study of Hydroxychloroquine Prior to Nephrectomy in Patients With Primary Renal Cell Carcinoma

National Institutes of Health (NIH)

University of Pittsburgh

MD, FACS

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma	NCT01144169	Renal Cell Carc...	Hydroxychloroqu...	19 Years -	University of Pittsburgh
Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma	NCT01144169	Renal Cell Carc...	Hydroxychloroqu...	19 Years -	University of Pittsburgh
Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma	NCT01144169	Renal Cell Carc...	Hydroxychloroqu...	19 Years -	University of Pittsburgh

Spots Global Cancer Trial Database for hydroxychloroquine (hc)